Last reviewed · How we verify

Gabren — Competitive Intelligence Brief

Gabren (PROGABIDE) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: progabide. Area: Neuroscience.

marketed progabide GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Gabren (PROGABIDE). Gabren works by enhancing the activity of the neurotransmitter GABA, which helps to calm down excessive neuronal activity in the brain.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Gabren TARGET PROGABIDE marketed progabide GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel
Klonopin clonazepam Generic (originally Roche) marketed Benzodiazepine [EPC] GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel 1975-06-04
Klonopin Klonopin Par Pharmaceutical, Inc. marketed GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (progabide class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gabren — Competitive Intelligence Brief. https://druglandscape.com/ci/progabide. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: